Lilly Invests Nearly $4 Billion in Vaccines: Acquires Three Biotech Companies

The American pharmaceutical giant Eli Lilly has announced that it will acquire three vaccine development companies in deals with a total value of up to $3.8 billion. This was reported by Reuters. The move demonstrates the company’s ambition to expand its presence in the field of infectious disease prevention.

The company will acquire Curevo, LimmaTech Biologics, and Vaccine Company—three biotech firms working on vaccines against various infectious diseases.

In recent years, Eli Lilly has significantly increased its financial capabilities thanks to the massive demand for its obesity medications. In 2026, the company’s acquisition spending has already exceeded the levels of previous years.

The deals also mark Lilly’s return to infectious diseases—a sector that had taken a backseat in recent years in favor of developing other therapeutic programs.

“These acquisitions reflect a focused strategy to prevent diseases at their source, rather than solely treating their consequences,” stated Daniel Skovronsky, Chief Scientific and Medical Officer at Eli Lilly.

According to Citi analysts, the focus of the three companies aligns with Lilly’s existing scientific interests—infections associated with long-term neurological and oncological risks.

Curevo could bring its shareholders up to $1.5 billion in the form of an upfront payment and subsequent milestone payments. Its primary project is amezosvatein—a vaccine against shingles.

LimmaTech Biologics will be acquired for up to $780 million. Its lead candidate, LTB-SA7, is in early-phase clinical trials and targets the bacterium Staphylococcus aureus—one of the leading causes of post-surgical infections.

The largest deal is for Vaccine Company, for which Lilly will pay up to $1.55 billion. The company is developing a vaccine against the Epstein-Barr virus—a widespread and highly contagious infection linked in numerous studies to an increased risk of certain oncological and neurological diseases.

According to market analysts, the acquisitions suggest that Lilly intends to become a significant player in the vaccine field as well.

Experts point out that the strategy was likely accelerated following the October appointment of Peter Marks, a former high-ranking official at the U.S. Food and Drug Administration, as the company’s head of infectious diseases.

“The size of the deals is relatively modest given the scale of the company, making the strategy even more logical,” commented Shams Afzal of Carnegie Investment Counsel.

With these acquisitions, Eli Lilly is sending a clear signal that, following its success in obesity drugs, the next major focus could be the prevention of infectious diseases through a new generation of vaccines.